Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.57

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been assigned an average recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $21.57.

A number of equities analysts have issued reports on the company. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, November 14th. Cantor Fitzgerald raised shares of Zevra Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 29th. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, November 20th.

Zevra Therapeutics Stock Down 0.8 %

Shares of ZVRA stock traded down $0.07 during midday trading on Friday, reaching $8.01. 52,883 shares of the stock were exchanged, compared to its average volume of 394,224. The firm has a market cap of $427.31 million, a PE ratio of -4.06 and a beta of 2.00. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The company's 50 day moving average is $8.20 and its two-hundred day moving average is $8.08. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76.

Insider Buying and Selling

In other news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the sale, the executive vice president now owns 29,486 shares in the company, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the sale, the chief executive officer now directly owns 222,060 shares of the company's stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock worth $674,176 in the last quarter. Corporate insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ZVRA. International Assets Investment Management LLC increased its holdings in Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after buying an additional 5,940 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Zevra Therapeutics during the 4th quarter valued at about $53,000. The Manufacturers Life Insurance Company grew its stake in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after acquiring an additional 2,452 shares during the period. Hunter Associates Investment Management LLC purchased a new position in shares of Zevra Therapeutics during the third quarter valued at approximately $92,000. Finally, XTX Topco Ltd purchased a new position in shares of Zevra Therapeutics during the third quarter valued at approximately $94,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.